TrialReader


Fluid Challenge and Plasma Volume, During Surgery

NCT05726136 — Phase 4, Recruiting, 60 participants, Joachim Zdolsek

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Comparison of Albumin and Ringer's Solution for Optimization of the Plasma Volume and Hemodynamics During Laparoscopic Surgery.

RegistryNCT05726136, acronym FC-VE
StatusRecruiting
PhasePhase 4
Study typeInterventional; randomized, parallel, masking: none, treatment
Enrollment60 (Estimated)
SponsorJoachim Zdolsek (Other)
ConditionsColorectal Cancer, Urologic Cancer, Gynecologic Cancer, Colorectal Disorders, Benign Neoplasm
Interventionsacetated Ringers, albumin 5%, albumin 20% (Drug)
Datesstart 2023-10-23, primary completion 2026-10-31 (estimated), completion 2026-10-31 (estimated), first posted 2023-02-13, last updated 2026-04-30
Locations1 site in Sweden

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Colorectal Cancer All trials for Urologic Cancer All trials of acetated Ringers All trials of albumin 5%

-Summary

A short bolus infusion of fluid, called "fluid challenge" is commonly recommended for fluid treatment during longer surgery. However a prolonged increase of the blood volume is a prerequisite to recommend the technique. The purpose with the study is to examine the plasma expanding effect of three different fluid challenge strategies (acetated Ringers 4 ml/kg body weight, albumin 5% 4 ml/kg body weight or albumin 20% 1 ml/kg body weight), using hemoglobin as a dilution indicator.

Expand all sections  ·  Collapse all

+Detailed description

60 patients scheduled for laparoscopic abdominal surgery, with a duration exceeding 90 minutes will be included in the study. These are randomized to three different groups (20 in each groups): The first group of patients will receive boluses of acetated Ringers 4 ml/kg body weight. The second albumin 4 ml/kg body weight and the third group albumin 20% 1 ml/kg body weight.

Hemoglobin, albumin and colloid osmotic pressure (COP) is sampled the day before surgery and in the morning directly prior to the anesthesia. Bioimpedance, urine osmolality and urine-creatinin are also measured. After induction of surgery a Cardio Q probe is inserted threw the nose into the esophagus, for circulatory measurements. Initial/baseline blood samples are taken after insufflation of carbon dioxide to the abdomen. Before every bolus of fluid and 5, (10), 15, 20, 30, 40, (50) and (60) minutes new blood samples are taken for determination of hemoglobin, albumin and COP. Artery blood gases are sampled 15 minutes after every infusion or depending on the clinical need.

+Arms and interventions

ArmTypeInterventionsDescription
acetated RingersExperimentalDrug: acetated RingersThe circulatory effect of a bolus infusion with 4 ml/kg body weight of acetated Ringers will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied.
albumin 5%ExperimentalDrug: albumin 5%The circulatory effect of a bolus infusion with 4 ml/kg body weight of Albumin 5% will be studied. If cardiac output increases with 10% a second bolus will be infused and further studied.
albumin 20%ExperimentalDrug: albumin 20%The circulatory effect of a bolus infusion with 1 ml/kg body weight of Albumin 20% will be studied. If cardiac output increase with 10% a second bolus will be infused and further studied.
  • acetated Ringers (Drug), also known as Ringer's acetate, ringer acetate, acetate Ringer´s: After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first fluid bolus is infused. Circulatory and volume effects are studied. If cardiac output increase a second bolus is infused and studied.
  • albumin 5% (Drug), also known as Albumin (Human) 5%, Human Albumin 5%: After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
  • albumin 20% (Drug), also known as Human Albumin 20%, Albumin (Human) 20%: After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.

+Outcome measures

Primary outcomes

  • Plasma volume expansion after a fluid bolus [60 minutes after an intravenous fluid bolus]: Plasma volume using hemoglobin as an indicator of dilution

Secondary outcomes

  • Fluid Balance [18 to 24 hours]: Calculations of fluid balance
  • Stroke Volume [60 minutes after an intravenous fluid bolus]: Change in stroke volume, measured with Cardio Q (oesophageal Doppler monitoring (ODM))
  • Arterial Blood Pressure [60 minutes after an intravenous fluid bolus]: Mean Arterial Pressure, measured with an arterial line.
  • Heart Rate [60 minutes after an intravenous fluid bolus]: Heart rate, measured with ECG and pulseoximeter.
  • Bioimpedance [18 to 24 hours]: Bioimpedance measures, resistance and impedance converted to volume of body fluid compartments.
  • Serum Creatinin [18 to 24 hours]: Serum Creatinin as a measure of kidney function
  • arterial pH [60 minutes after an intravenous fluid bolus]: Influence of a fluid bolus on arterial blood gases
  • arterial Base Excess [60 minutes after an intravenous fluid bolus]: Influence of a fluid bolus on arterial blood gases
  • arterial serum sodium [60 minutes after an intravenous fluid bolus]: Influence of a fluid bolus on Sodium concentration
  • arterial serum chloride [60 minutes after an intravenous fluid bolus]: Influence of a fluid bolus on Chloride concentrations

+Eligibility

Sex: All, ages: 18 Years to 85 Years

Inclusion Criteria:

* Written consent to participate in the study
* For women: relevant contraceptive, menopausal or a negative pregnancy test.
* ASA category I to III
* Laparoscopic abdominal surgery, with a duration of at least 90 minutes.
* 18 to 85 years

Exclusion Criteria:

* Patients with known cardiac failure
* <18 or >85 years
* known allergy to albumin
* extracellular hyperhydration or hypervolemia
* kidney failure
* pregnancy or planned pregnancy

+Locations (1)

FacilityCityCountryStatus
Vrinnevi HospitalNorrköping, Östergötland CountySwedenRecruiting

+Study documents

+Investigators

  • Joachim Zdolsek, MD PhD, Principal investigator, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

My Notes